Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Deborah Grayson, a top pharmacist and nutritional therapist, has warned that weight loss medication can cause an inflamed ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

Mantzoros reportedly suggests starting treatment “slow and low” to minimize the effects. Cost is another factor, as insurance ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...